Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial

JAMA

Volumn 298, Issue 7, 2007, Pages 743-753

  Hildesheim, Allan ^a   Herrero, Rolando ^b,c   Wacholder, Sholom ^a   Rodriguez, Ana C ^c   Solomon, Diane ^a   Bratti, M Concepcion ^c   Schiller, John T ^a   Gonzalez, Paula ^c   Dubin, Gary ^d   Porras, Carolina ^c   Jimenez, Silvia E ^c   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Proyecto Epidemiologico Guanacaste   (Costa Rica)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; HEPATITIS A VACCINE; VIRUS DNA; VIRUS RNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CHEMOLUMINESCENCE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COSTA RICA; CYTOLOGY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MOLECULAR HYBRIDIZATION; NEISSERIA GONORRHOEAE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SMOKING; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS LOAD;

EID: 34547912100     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.7.743     Document Type: Article

References (28)

1. Schiffman MH, Hildesheim A. Cervical cancer. In: Schottenfeld D, Fraumeni JFF Jr, eds. Cancer Epidemiology and Prevention. Oxford, England: Oxford University Press; 2006:1044-1067.
2. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278.
3. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 viruslike particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
5. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
6. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107(1):18-27.
7. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(suppl 3):S106-S113.
8. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116(5):1167-1173.
9. Nardelli-Haefliger D, Wirthnew D, Schiller JT, et al. Specific antibody levels at the cervix are menstrual-cycle dependent in women vaccinated with human papillomavirus type 16 virus like particles. J Natl Cancer Inst. 2003;95(15):1128-1137.
10. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24(33-34):5937-5949.
11. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24(27-28):5571-5583.
12. Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 viruslike particles. J Infect Dis. 2003;188(2):327-338.
13. Pinto LA, Castle PE, Roden RB, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine. 2005;23(27):3555-3564.
14. Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a viruslike particle vaccine. J Virol. 2002;76(15):7832-7842.
15. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus viruslike particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 1998;240(1):147-157.
16. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. Viruslike particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996;219(1):37-44.
17. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76-84.
18. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103(2):304-309.
19. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362.
20. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus testing for triage of women with cytologic evidence of lowgrade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000;92(5):397-402.
21. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8):2508-2517.
22. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153(6):1731-1739.
23. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44(9):3292-3298.
24. Baay MF, Quint WG, Koudstaal J, et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol. 1996;34(3):745-747.
25. Schachter J, Hook EW III, McCormack WM, et al. Ability of the Digene Hybrid Capture II test to identify Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens. J Clin Microbiol. 1999;37(11):3668-3671.
26. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
27. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20):2101-2104.
28. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-1765.